Last reviewed · How we verify
prostaglandins E2
Prostaglandin E2 (PGE2) binds to EP prostanoid receptors on cell surfaces to modulate inflammation, immune responses, and tissue remodeling.
Prostaglandin E2 (PGE2) binds to EP prostanoid receptors on cell surfaces to modulate inflammation, immune responses, and tissue remodeling. Used for Graft-versus-host disease (GVHD) or related immune/inflammatory conditions (Phase 3 status suggests clinical development in this area).
At a glance
| Generic name | prostaglandins E2 |
|---|---|
| Also known as | dinoprostone slow release pessary |
| Sponsor | Tel-Aviv Sourasky Medical Center |
| Drug class | Prostanoid agonist |
| Target | EP prostanoid receptors (EP1, EP2, EP3, EP4) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
PGE2 is an endogenous eicosanoid that acts through four G-protein coupled EP receptors (EP1–EP4), triggering diverse downstream signaling pathways. Depending on the receptor subtype and tissue context, PGE2 can suppress or enhance inflammatory responses, promote vasodilation, inhibit platelet aggregation, and modulate bone metabolism and immune cell differentiation. Exogenous PGE2 administration aims to harness these pleiotropic effects therapeutically.
Approved indications
- Graft-versus-host disease (GVHD) or related immune/inflammatory conditions (Phase 3 status suggests clinical development in this area)
Common side effects
- Flushing
- Headache
- Gastrointestinal disturbance
- Hypotension
Key clinical trials
- An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (PHASE2)
- Dexamethasone as ESPB Adjuvant in Lumbar Laminectomy (PHASE3)
- Comparison of Conventional and Cu-NiTi Archwires Regarding Clinical Efficiency and Pain Intensity Using Prostaglandin E2 Biomarker During Alignment and Leveling (NA)
- Evaluation of the Biomechanical Response of Orthodontic Tooth Movement to Clear Aligner vs Fixed Orthodontic Appliance (NA)
- Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates
- Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies (PHASE3)
- Mechanical Dilation of the Cervix in a Scarred Uterus (NA)
- Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- prostaglandins E2 CI brief — competitive landscape report
- prostaglandins E2 updates RSS · CI watch RSS
- Tel-Aviv Sourasky Medical Center portfolio CI